Publications by authors named "Lauren Rowland"
Article Synopsis
- * Researchers analyzed data from 1,096 patients using various definitions of hyperdiploidy to assess the best predictors for event-free survival (EFS) and relapse rates; findings indicated that the DNA index (DI1.16-1.6) was the most favorable criterion.
- * The results highlight that hyperdiploidy and certain subgroups respond well to specific drugs, with distinct sensitivities to asparaginase and mercaptopurine based on particular chromosomal traits, suggesting a more personalized approach to treatment for
Article Synopsis
- Resistance to chemotherapy in acute lymphoblastic leukemia (ALL) is a significant reason for treatment failure, with challenges in current testing methods for drug sensitivity.
- A new fluorescence imaging method allows for efficient profiling of drug sensitivity in primary ALL cells using co-culture with stromal cells and a panel of 40 drugs, aiming to identify individual resistance patterns.
- This automated approach enhances testing efficiency by needing fewer cells and reduces the labor and time required, integrating drug sensitivity data with genomic profiling for a more precise treatment strategy.
Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted based on clinical features, leukemia genomics and minimal residual disease (MRD); however, the pharmacological basis of these prognostic variables remains unclear. Analyzing samples from 805 children with newly diagnosed ALL from three consecutive clinical trials, we determined the ex vivo sensitivity of primary leukemia cells to 18 therapeutic agents across 23 molecular subtypes defined by leukemia genomics. There was wide variability in drug response, with favorable ALL subtypes exhibiting the greatest sensitivity to L-asparaginase and glucocorticoids.
View Article and Find Full Text PDFArticle Synopsis
- T-cell acute lymphoblastic leukemia (T-ALL) is a serious blood cancer that shows varying drug responses, with about 44% of children and 17% of adults responding well to the drug dasatinib.
- Research found that the activation of a specific signaling pathway (preTCR-LCK) is key to why some T-ALL cases are sensitive to dasatinib, while other cases are resistant to a different drug called venetoclax.
- The study highlights that the developmental stage of T-cells in leukemia influences which signaling pathways are active, suggesting potential for developing targeted therapies based on a patient's specific leukemia characteristics.
CRLF2-rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) accounts for more than half of Philadelphia chromosome-like (Ph-like) ALL and is associated with a poor outcome in children and adults. Overexpression of CRLF2 results in activation of Janus kinase (JAK)-STAT and parallel signaling pathways in experimental models, but existing small molecule inhibitors of JAKs show variable and limited efficacy. Here, we evaluated the efficacy of proteolysis-targeting chimeras (PROTACs) directed against JAKs.
View Article and Find Full Text PDFIn this research we report that the sepG1 mutation in Aspergillus nidulans resides in gene AN9463, which is predicted to encode an IQGAP orthologue. The genetic lesion is predicted to result in a G-to-R substitution at residue 1637 of the 1737-residue protein in a highly conserved region of the RasGAP-C-terminal (RGCT) domain. When grown at restrictive temperature, strains expressing the sepG (sepG1) allele are aseptate, with reduced colony growth and aberrantly formed conidiophores.
View Article and Find Full Text PDF